BBC

Virtus LifeSci Biotech Clinical Trials ETF
N/A

N/A
  • Overview
  • Efficiency
  • Tradability
  • Fit

BBC Fund Description

The Virtus LifeSci Biotech Clinical Trials ETF tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials.

BBC Factset Analytics Insight

BBC charges a stiff fee for focused exposure to biotech companies with lead drugs still in various phases of clinical trials. Given the low historical success rates in clinical trials, the fund is a high-risk and high-reward bet on a small subset of biotech companies. As such, if you're looking for broad biotech exposure, you won't find it in BBC, which carries an elevated beta and ends up with a basket for primarily small- and micro-cap stocks. That micro-heavy basket means that larger traders might face some obstacles to efficient block execution. Retail traders should likewise handle with care, as volume is weak and spreads can be sizeable. BBC has attracted middling investor interest, but closure risk cannot be dismissed.

BBC MSCI ESG Analytics Insight

The MSCI ESG Fund Quality Score measures the ability of ETF underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors, as determined by MSCI ESG Research LLC. As of December 13, 2017 the Virtus LifeSci Biotech Clinical Trials ETF MSCI ESG Fund Quality Score is 3.99 out of 10.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. BBC ranks in the 5th percentile within its peer group and in the 8th percentile within the global universe of all funds in MSCI ESG Fund Metrics coverage.

  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
COMPARE
RESET
Select ETFs to compare their performance:

BBC Top 10 Countries

BBC Top 10 Sectors

BBC Top 10 Holdings View All

BBC Summary Data

Virtus
12/16/14
Open-Ended Fund
0.79%
$35.40M
$382.52K
0.31%

BBC Portfolio Data

$1.74B
-7.16
5.70
0.00%
N/A
73

BBC Index Data

Equal
Proprietary
Thomson Reuters US Biotechnology & Medical Research

Related ETFs to BBC

XBI, FBT, CNCR, BBP, IBB
Total Return
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max

BBC Portfolio Management

0.79%
--
--
--

BBC Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

BBC Fund Structure

Open-Ended Fund
No
Yes
No Policy
N/A
N/A
High
Daily
Bats Book Viewer
TOP OF BOOK
SHARES/SIZEPRICE
ASKS----
----
----
----
----
BIDS----
----
----
----
----
LAST 10 TRADES
TIMEPRICESHARES
14:55:1327.197
10:56:4527.821
------
------
------
------
------
------
------
------
Bats BZX Real-time Quote - 17:30:41
Daily Spread
Premium/Discount
Volume

BBC Factset Analytics Block Liquidity

As of 12/14/17
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of BBC. BBC is rated a 4 out of 5.

BBC Tradability

13,727
$382.52K
9,088
$252.05K
0.31%
$0.08
0.02%
1.29% / -0.86%
None
100.00%
50,000
0.18
0.04%
0.26%
--
$27.83
4

BBC Geographic Exposure

BBCSegment Benchmark
100.00% 100.00%

BBCSegment Benchmark
100.00% 100.00%
0.00% / 0.00% 0.00% / 0.00%

BBC Performance Statistics

0.66
1.44
1.21
1.37
1.09%
Thomson Reuters US Biotechnology & Medical Research

BBC MSCI ESG Ratings

3.99 / 10
4.52
8.43
1.19%
--
25.04

BBC BENCHMARK COMPARISON

    BBC
    73 Holdings
    Segment Benchmark
    123 Constituents
    Shared Holdings
    60 (Count)
     
    17.99% (Weight)
BBCSegment Benchmark
52.28% 0.00%
30.15% 20.66%
14.90% 50.18%
2.68% 29.16%
146.22 -7.16
0.73% --